ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 14, 2022 08:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Announces Multiple Publications Highlighting the Potential Utility of Lysins for the Treatment of Bone and Joint Infections
September 12, 2022 07:32 ET
|
ContraFect Corporation
YONKERS, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect Announces Presentation of New Clinical Data From a Study Using Exebacase in the LysinDAIR Procedure on Patients With Chronic Knee Prosthetic Joint Infection
September 12, 2022 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
Presentations at ASM Microbe Conference Demonstrate Potential of ContraFect’s Direct Lytic Agents (DLAs) to Address MRSA Infections
June 14, 2022 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., June 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 20, 2022 08:30 ET
|
ContraFect Corporation
YONKERS, N.Y., May 20, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) (ContraFect), a late clinical-stage biotechnology company focused on the discovery and development of direct...
ContraFect Reports First Quarter 2022 Financial Results and Provides Business Update
May 16, 2022 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect Data Presentations at the 32nd Annual ECCMID Meeting Highlight the Potential of Engineered Lysin CF-370 to Improve Clinical Outcomes and Suppress Antimicrobial Resistance Compared to Antibiotics Alone
April 27, 2022 08:00 ET
|
ContraFect Corporation
YONKERS, N.Y., April 27, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect Announces Multiple Presentations of New Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Address Antimicrobial Resistance at the 32nd Annual ECCMID Meeting
April 18, 2022 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., April 18, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Update
March 24, 2022 08:00 ET
|
ContraFect Corporation
YONKERS, N.Y., March 24, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect Announces Award from the Cystic Fibrosis Foundation to Evaluate Exebacase as a Potential Treatment for Serious MRSA Lung Infections Associated with Cystic Fibrosis
January 06, 2022 16:05 ET
|
ContraFect Corporation
YONKERS, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...